There were 143 patients who received hormonal therapy, with higher rates of ADT in salvage ablation (HR 1.42, 95% CI 0.97, 2.08, p = 0.068): Ongoing trials include the SAFE Pilot Trial of salvage ...

The study found that Focal One's treatment methods match up with the gold star standard of surgery, and improve quality of life outcomes.

“Our findings highlight the coordinated interplay between GCN2 and p53 regulation during nutrient stress and provide insight into how they could be targeted in developing new therapeutic strategies ...

As noted earlier, the bones are the most common site of prostate cancer metastases. Sometimes, in people who have not had screening, it may be the first symptom of the disease. Bone metastases can ...

Comparison of Industry-Sponsored Trials (IST) and Investigator-Initiated Trials (IIT) in Advanced Genitourinary Cancers in the United States, Canada, United Kingdom, and France - Beyond the Abstract ...

CEO of Bayer UK & Ireland, Antonio Payano, said: “We are delighted that men with prostate cancer in England will have early access to another innovative treatment option.

Advanced Imaging Uncovers Hidden Metastases in High-Risk Prostate Cancer Cases Jan. 3, 2025 — A new study has found that many cases of high-risk nonmetastatic hormone-sensitive prostate cancer ...

Here the authors report the results of a phase 1 trial of PSCA-directed autologous CAR-T cells with pharmacological activation by rimiducid in patients with metastatic pancreatic or prostate cancer.

Padeliporfin potassium is under clinical development by ImPact Biotech and currently in Phase I for Non-Small Cell Lung Cancer.

Aquablation therapy combines real-time, multi-dimensional imaging, automated robotics, and heat-free waterjet ablation for targeted ... and early stages of prostate cancer, men may not have ...

To date, there is no sufficient evidence to support the use of any upstream therapy after AF catheter ablation. Larger registries and controlled clinical trials in well-defined patient groups and ...

Lake Street analyst Ben Haynor maintained a Buy rating on Profound Medical (PRN – Research Report) today and set a price target of $17.00. The ...